SENTISS PHARMA
GenericsSENTISS PHARMA is a generic drug manufacturer focused on Cardiovascular, Neurology.
SENTISS PHARMA's Key Drugs
SENTISS PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
SENTISS PHARMA's Recent FDA Approvals
New NDA/BLA approvals for SENTISS PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
SENTISS PHARMA's Therapeutic Areas
SENTISS PHARMA's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SENTISS PHARMA's Top Competitors
SENTISS PHARMA's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SENTISS PHARMA Pipeline Snapshot
Active clinical trials for SENTISS PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-05-08
- Latest
- 2023-05-08
- Applications
- 1